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Public Health at Risk: a US Free Trade Agreement could threaten access to 
medicines in Thailand 
Abstract 
Even though the world faces the threat of potential new epidemics like avian influenza, the effects of 
trade rules on public health attract little attention. Governments recently reaffirmed their commitment to 
meet the Millennium Development Goals which include combating HIV/AIDS, malaria and other major 
diseases, yet little attention is given to the implications of United States Free Trade Agreements (US 
FTAs) with developing countries such as Thailand, for access to affordable medicines to treat those 
diseases. These FTAs do much more than regulate tariffs for cross-border trade in goods and services: 
they change the rules of intellectual property protection in ways that will undermine public health by 
limiting access to affordable medicines. This report seeks to draw attention to the potential effect on 
access to medicines of new intellectual property rights protections in US J:TAs. It is part of Oxfam's 
broader critique of trade rules in FTAs that have adverse effects on development and poverty. reduction. 1 
Thailand is a positive example of a developing country that has created effective programs to address the 
HIV/AIDS epidemic, having invested in prevention and treatment early on. More than 1 million women, 
men, and children have contracted HIV in Thailand and more than 500,000 people have died of AIDS since 
the outbreak of the epidemic. Thailand's prevention efforts, which helped avoid more than 5 million new 
infections, are widely recognized as a success story among developing countries. Nevertheless, there are 
still around 20,000 new infections each year, with half of new adult infections occurring among women. 
By preventing a much larger epidemic, Thailand avoided much larger treatment costs. For every baht 
invested in prevention and treatment in the 1990s, Thailand saved 43 baht in added treatment costs. In 
2000 the Ministry of Public Health created the National Access to Antiretroviral Program for People Living 
with HIV/AIDS (NAPHA), providing a wide range of triple-drug antiretroviral (ARV) therapy. Two years later, 
the Government Pharmaceutical Organization (GPO) began producing its first ARV triple drug 'cocktail' 
called GPO-vir for 1,200 baht ($ 31) per patient per month, compared with 18,620 baht ($ 490) for 
importeo, brand-name drugs. As a result of these efforts, the Thai government has been able to provide 
ARV drugs to increasing numbers of people who need them. The most important factor making this 
possible has been the government's ability to procure inexpensive generic drugs. With the introduction of 
GPO-vir, the HIV/AIDS treatment program was expanded more than eight-fold from 20012003 with only a 
40 per cent increase in bUdget. Thanks to the availability of these generic medicines, the government is 
able to offer life-saving HIV/AIDS medicines to approximately 80,000 people, with plans to expand the 
program in coming years. 
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Public Health at
Risk




New stringent drug patent and marketing rules being negotiated
in a Free Trade Agreement (FTA) between the US and Thailand
would limit competition and reduce access to affordable
medicines in Thailand. This would threaten the future of existing
successful Thai HIV/AIDS treatment programmes, which rely on
inexpensive generic drugs, and thus deprive thousands of
people of effective treatment. Oxfam opposes an FTA with
intellectual property rules that exceed the standards agreed at
the World Trade Organization.
Glossary
ARV: antiretroviral drugs are medicines for the treatment of infection by
retroviruses, primarily HIV. Different classes of antiretroviral drugs act at
different stages of the HIV life cycle.
Baht: Thai currency: 38 baht is roughly equivalent to $1.00, €0.80, and
£0.55.
Compulsory license: a government measure that permits a patent to be
overriden so that another party (public or private) can use the patent after _
paying reasonable compensation to the patent holder.
Fast Track: (also known as the Trade Promotion Authority or TPA). US
legislation that authorizes the Executive branch to negotiate trade
agreements and then bring them to Congress for a 'yes' or 'no' vote without
any possibility to amend them.
FTA: Free Trade Agreement.
GPO: Government Pharmaceutical Organization, a state enterprise under the
Ministry of Public Health in Thailand.
NAPHA: TFlaiiancl's National Access fo Antiretroviral Program for People
Living with HIV/AIDS.
NGO: Non-governmental organization.
Parallel importation: the importation of a patented drug from a third country
where its market price is lower than that in the country of origin due to the
differential pricing practice by drug companies.
RTA: Regional Trade Agreement.
TRIPS: Trade-Related Aspects of Intellectual Property Rights. The INTO
TRIPS Agreement establishes minimum levels of protection that each
government has to give to the intellectual property of other INTO members.
The agreement was included in the 1986-1994 Uruguay Round global trade
negotiatIons that concluded with the formation of the WTO. It applies to all
members of the WTO.
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Even though the world faces the threat of potential new epidemics like avian
influenza, the effects of trade rules on public health attract little attention.
Governments recently reaffirmed their commitment to meet the Millennium
Development Goals which include combating HIV/AIDS, malaria and other
major diseases, yet little attention is given to the implications of United States
Free Trade Agreements (US FTAs) with developing countries such as
Thailand, for access to affordable medicines to treat those diseases. These
FTAs do much more than regulate tariffs for cross-border trade in goods and
services: they change the rules of intellectual property protection in ways that
will undermine public health by limiting access to affordable medicines.
This report seeks to draw attention to the potential effect on access to
medicines of new intellectual property rights protections in US J:TAs. It is part
of Oxfam's broader critique of trade rules in FTAs that have adverse effects
on development and poverty. reduction. 1
Thailand is a positive example of a developing country that has created
effective programs to address the HIV/AIDS epidemic, having invested in
prevention and treatment early on. More than 1 million women, men, and
children have contracted HIV in Thailand and more than 500,000 people
have died of AIDS since the outbreak of the epidemic. Thailand's prevention
efforts, which helped avoid more than 5 million new infections, are widely
recognized as a success story among developing countries. Nevertheless,
there are still around 20,000 new infections each year, with half of new adult
infections occurring among women.
By preventing a much larger epidemic, Thailand avoided much larger
treatment costs. For every baht invested in prevention and treatment in the
1990s, Thailand saved 43 baht in added treatment costs. In 2000 the Ministry
of Public Health created the National Access to Antiretroviral Program for
People Living with HIV/AIDS (NAPHA), providing a wide range of triple-drug
antiretroviral (ARV) therapy. Two years later, the Government
Pharmaceutical Organization (GPO) began producing its first ARV triple drug
'cocktail' called GPO-vir for 1,200 baht ($ 31) per patient per month,
compared with 18,620 baht ($ 490) for importeo, brand-name drugs.
As a result of these efforts, the Thai government has been able to provide
ARV drugs to increasing numbers of people who need them. The most
important factor making this possible has been the government's ability to
procure inexpensive generic drugs. With the introduction of GPO-vir, the
HIV/AIDS treatment program was expanded more than eight-fold from 2001-
2003 with only a 40 per cent increase in bUdget. Thanks to the availability of
these generic medicines, the government is able to offer life-saving HIV/AIDS
medicines to approximately 80,000 people, with plans to expand the program
in coming years.
But as Thailand maintains and scales up treatment of people with HIV/AIDS,
there is trouble on the horizon. Over time, increasing numbers of Thailand's
population with HIV/AIDS will need access to 'second-line' ARVs,because
viruses typically develop resistance to drugs after a period of time, and
treatment with 'first-line' regimens will eventually fail. Local production of
GPO-vir is legal because these first-line drugs were invented before Thailand
introduced patent protection for medicines in 1992 and, therefore, they could
not be patented in the country. However, second-line therapies were
developed more recently and are patented in Thailand, where they cost, on
average, 14 times more than first-line treatments.
Thus, the future of treatment program in Thailand could be threatened if the
United States succeeds in pressuring the Thai government to accept
stringent new drug patent and marketing rules during FTA negotiations. US
pressure to strengthen intellectual property protection is not new in Thailand:
it dates back 20 years and includes denying trade preferences under the US
General System of Preferences in 1989 and 1991. Facing intense pressure,
Thailand amended its existing patent law in 1992 to allow patents on
pharmaceuticals, and extended patent life from 15 to 20 years. The law was
amended again in 1999 to comply with the wro Agreement on Trade
Related Aspects of Intellectual Property Rights (TRIPS).
As permitted by TRIPS, the Thai patent law currently allows flexibilities that
help lower the price of medicines, such as compulsory licensing, which
allows the government to override a patent to meet public health needs.
According to a recent World Bank report, '... by exercising compulsory
licensing to reduce the cost of second-line therapy by 90 per cent, the Royal
Thai Government would reduce its future budgetary obligations by 3.2 billion
discounted dollars (127 billion discounted baht) through the year 2025.'
But it is likely that provisions in a US-Thailand FTA would limit the
government's flexibility to issue compulsory licenses, and would create a
number of other obstacles to production and marketing of generic drugs.
These new intellectual property rules exceed Thailand's obligations under
TRIPS and could undermine the country's ability to provide affordable ARVs
and other medicines to its population.
The US proposal on intellectual property rights for medicines in the US-
Thailand FTA includes provisions similar to those in other US FTAs. In some
cases, provisions are stronger than in most previous agreements and
include, for example, extension of the patent term, protection of test data, and
linkage between marketing approval and patent status. Additional provisions
that have been included in some previous US FTAs, such as restrictions on
the grounds for compulsory licensing, expansion of the patent scope, and
limits to challenging potentially invalid patents, will further limit the use of
important existing f1exibilities in drug patent and marketing rules. The
incorporation of these so-called 'TRIPS-plus' rules into this FTA could
seriously hamper Thailand's HIV/AIDS programs, thus depriving thousands
of people of effective treatment.
Oxfam recommends that no intellectual property provisions beyond the
commitments established in TRIPS be included in any trade agreement
between the United States and developing countries, such as Thailand.
US-Thailand FTA negotiations should be halted in order to carry out and take
into account independent studies on the potential impact of proposed
provisions on public health. Any future negotiations should involve greater
transparency, including public disclosure of the negotiating text, and should
take into account concerns and proposals of civil society stakeholders. In
negotiating any trade agreement with the United States, Thailand should
ensure that it can maintain and enact laws and create policies which uphold
the right to public health and which promote broad access to safe, effective
and affordable medicines. No trade agreement should negotiate away public
health.
1 Introduction
'The effects ofantiretroviral drugs are clear. They improve patients' lives and
help them to resume their daily activities. Patients also have a better immune
system and have better resistance to opportunistic diseases. This is obvious
when patients walk in my office with a smile/ having gained their weight back
to normal. After taking antiretroviral drugs correctly and regularly/ patients
look well and are like any healthy men and women.'
(Dr. Janjira Jirtaknatee, physician)
Access to F.JV/ .A...IDS medicines trLakes a huge dia.+fererLce to tile lives of
- infected people and their families. Not only do these medicines help
people live longer, but they also greatly improve the quality of their
lives, reduce the stigma ap.d discrimi..."'1.ation that they might
experience, and enable them to contribute to the economic and social
welfare of their families; their communities, and their countries as a
whole. Thailand is a positive example of a developing country that
has created effective HIV/ AIDS treatment programs, with beneficial
results for its population. It has a health-care system that can deliver
antiretroviral (ARV) therapy and other treatments to those in need.
Thanks to the availability of affordable generic medicines the
goverIllilent is able to offer life-saving HN/ AIDS medicines to
approximately 80,000 people, 2 with plans to expand the program in
coming years.
Thai programs to provide medicines for people with HIV/ AIDS rely
on inexpensive drugs. However, the future of treatment programs in
Thailand could be threatened if the United States succeeds in
pressurmg Thailand to accept stringent new drug patent and
marketing rules under a bilateral Free Trade Agreement (FTA). These
new rules could undermine the ability of Thailand to provide
affordable medicines to its population.
Negotiations for a PTA were launched in June of 2004, and have
proceeded slowly for the last two years. In nine other PTA
negotiations completed in the last four years, the US has consistently -
and successfully - pressured other countries to accept new, strict
intellectual property rules which can seriously obstruct efforts to
lower the price and increase the accessibility of life-saving medicines.
These new rules exceed the standards incorporated in theWTO
Agreement on Trade Related Aspects of Intellectual Property Rights
(TRIPS) and:
• prevent or delay the introduction of affordable generic medicines,
by restricting or limiting the use of public health safeguards in the
TRIPS Agreement; and
• undermine the implementation of the 2001 WIO Doha Declaration
on TRIPS and Public Health that reconfirmed the primacy of
public health over private patents.
The incorporation of such 'TRIPS-plus' standards into the US-
Thailand FTA could seriously hamper Thailand's HIV/ AIDS
programs by depriving thousands of people of effective treatment
Oxfam believes the United States should support the long-term
sustainability of Thailand's EN/ AIDS programs, rather than
undermine it by seeking stronger intellectual property standards
through backdoor restrictions in the US-Thailand FTA.
While this paper focuses on the issue of HN/ AIDS treatment in
Thailand, it is important to note that the harmful impact of stricter
intellectual property rules applies to a much broader range of diseases
and treatmentS including opportunistic infections which frequently
afflict people living with HN/ AIDS, other infectious diseases, and
chronic illnesses such as heart disease and cancer.
2 HIV/AIDS in Thailand
More than 1 million women, men, and children have contracted HN
in Thailand, and more than 500,000 have died of AIDS since the
outbreak of the epidemic. In spite of successful prevention efforts,
there are still around 20,000 new infections each year. 3
Widespread transmission of HN in Thailand occurred in the late
1980s. Between 1988 and 1989, the rapid transmission of HN was
apparent among injecting drug-users who showed over 50 per cent
HIV prevalence in some provinces. From 1993 to 1997, 8,325 cases
were reported, but it is believed that HN infections spread most
rapidly among sex workers. Nearly half the sex workers in Chiang
Mai, a northern province of Thailand, were infected with HIV. 4 The
high rate of infection among female sex workers led to the rapid
transmission of HIV/AIDS to their male clients, and from infected
males to their wives, partners and children.
Aggressive prevention efforts have helped to slow the spread of the
disease and it is estimated that more than 5 million infections have
been prevented as a result. 5 Nevertheless, there is evidence that
infections are growing in the general population and among specific
groups. For example, the rate of HIV infections among teenagers rose
from 11 per cent in 2001 to 17 per cent the following year. 6
Women have been heavily affected by the pandemic. At the early
stage of the pandemic, around one:-third of adults living with
HIV/ AIDS in Thailand were women, often infected by husbands or
partners wh'O had become iin:facted. by the virus during commercial
sex. While most HN tramlIliSb'ion in Thailand in. the early 1990s
occurred between sex workers and their clients, aro1Lmd 50 per cent of
new infections were taking place between. spouses ten years later.7
Half of new adult infections are now occmrirl.g among women. The
current figure shows that 70 per cent of young people between the
ages of 15 and 24 who are living with HIV/ AIDS are female. 8 _lhe
rate of HIV infection aD:wng pregnant women is relative1y11igh but
variable. From 0.5 per rent in 1990, HN prevalenc:}~among pregnant
wonten increased to.2.4 per cent"in 1995, btitdecreased to 1.18 and
1.09 in 2003 and 2004 respedivery. 9
In addition to the direct impact of HN/ AIDS, women often face a
disproportionate burden of caring for sick family members or younger
siblings, thus restricting employment or educational opportunities. In
many cases, girls are much more likely to be withdrawn from school
to perform caretaking tasks. -
In recent years, the Thai government has taken important steps to
contain the epidemic through the introduction of a strong prevention
program which promotes condom use, provides medicines to prevent
mother-to-child transmission, and provides a treatment program.
With relatively successful programs, Thailand has contained the
spread of the disease, and HN prevalence has been progressively
reduced. By preventing a much larger epidemic, Thailand has
avoided much larger treatment costs. For every baht invested in
prevention and treatment in the 1990s, Thailand saved 43 baht in
added treatment costs. 10 Thailand's prevention efforts are widely
recognized as a success among developing countries. 11
3 The HIV/AIDS treatment program
'The treatment ofpeople living with HIVjAIDS has come a long way. There
is an increase in the variety ofARV drugs available in Thailand, particularly
the local-made ARV drugs. Success ofHIV treatment will occur ifpatients
have access to medicine... The increased price afARV drugs will have a
major impact on people who buy ARV drugs by themselves. It will also affect
the government's budget on health care schemes. We have to see the new
policy that the government will create if there is a significant increase in the
price ofARV drugs.'
f'Naravhuti Kowatcharakul, physician)
Thailand's initial policy response to HIV/ AIDS focused primarily on
preventing the spread of the epidemic. Medical treatment was
provided for the prevention of opportunistic infections only. No ARV
treatment was provided to HIV-related patients in the early stages of
the HIV/ AIDS campaign.
The Thai government subsequently realized that while preventing
new HIV infections was crucial, a treatment program was also needed
for those who had already contracted the virus. In 1992, the Thai
Ministry of Public Health started to subsidize a treatment program of
ARV drugs for a small number of people with HIV/ AIDS. At the
beginning, mono-ARV the~apies involving zidovudine (AZT) were _
provided. Thgil,€,therapies proved to be, inefficient and ineffective as
theyirus tep-ded to mutate and become resistant to the medication. In
1995, the Ministry of Public Health switched to dual therapy using a
combination of two ARV drugs and two years later to triple-drug
therapy using a combination of t:hTee ARVs.
In 2000, the Thai Ministry of Public Health initiated the 'Access to
Care' (ATC) pilot program to evaluate the feasibility of the
administration of free ARV treatment to a group of 630 HIV- infected
patients in six northern provinces with the highest number of AIDS
cases. The objectives were to identify critical issues for
implementation prior to further expansion of the program.l2
From 2001-2003, the ATC pilot program developed into the 'National
Access to Antiretroviral Program for People Living with HrV'/ AIDS'
(NAPHA), which provided a wide range of triple-drug ARV therapy.
Under this program, around 400 public hospitals began dispensing
ARV drugs. Beneficiaries are selected by local committees comprising
government officials, health workers and NGO representatives. The
committees base decisions on medical assessments of HIV-infected
patients to determine whether they meet the treatment criteria (for
example, patients with a depressed immune system) set out in the
guidelines developed by the national committee. Patients selected by
the committee receive ARV drugs free of charge. These drugs 9-re
allocated to local hospitals throughout the country on a quota system.
Small state-funded hospitals receive ARV drugs for 20 people at a
time, while larger hospitals receive a quota of drugs for 40 people.
In 2002, the Thai government initiated a national health insurance
system which covers 95 per cent of the population. The health
insurance system provides basic health insurance for a fee of 30 baht
($ 0.79) per visit to a clinic. 13 The '30 baht' system did not initially
cover ARV treatment, due to the high costof drugs and limited public
budgets. Although in October 2005 the government announced it
would include ARV treatment in the '30 baht' scheme, the principles
and ways to implement the system are still under discussion.
Despite obstacles, the Thai government has been able to provide ARV
drugs to increasing numbers of people. This is partly due to increased
budget allocations for ARV treatment: the 2004 ARV budget grew to
800 million baht from 300 million baht in 2003. 14 But the most
important factor has been the ability of the government to procure
inexpensive generic drugs.
Initially, Thailand's drug treatment program distributed branded
drugs which cost more than 380,000 baht ($ 10,000) per person per
year. These prices were far beyond the government's limited budget.
In 2002, the Government Pharmaceutical Organization (GPO), a state
enterprise under the NliniStry of Public Health, successfully produced
its first ARV 'cocktail' called GPO-vir. GPO-vir, a fixed-dose
combination of three drugs (stavudine, lamivudine and nevirapine) has
become a cheap and affordable ARV treatment for many people with
HNI AIDS in Thailand. GPO-vir costs 1,200 baht ($ 31) per patient
per month compared to 18,620 baht ($ 490) per patient per month for
imported, brand-name drugs.
Between 2001 and 2003 the HIV-treatment program expanded more
than eight-fold with only a 40 per cent increase in budget. The
number of people onARV treatment reached 50,000 at the end of
2004, and is approximately 80,000 today. 15
Local generic production of these HNI AIDS medicines is legal
because these drugs were invented before Thailand introduced
product-patent protection in 1992. Therefore, they could not be
patented in the country.
However, procurement of other HIV/ AIDS drugs has been hampered
by the fact that they were patented in Thailand after 1992. Merck's
ejavirenz is one of those drugs. For drugs under patent, the
government cannot legally import or produce generic versions
without using a compulsory license to override the patent (this is
permitted under WTO TRIPS rules). Access to treatment regimes
other than the standard 'first line' ARVs is important. For example,
some people develop adverse reactions to nevirapine (one of the
components in the Thai government"s generic triple drug therapy),
including liver and kidney damage, so they need to be given
alternative drugs such as Merck's efavirenz. However, efavirenz is
patented and is more expensive, nearly doubling the daily cost of
mvI AIDS medicines from 40 to 75 baht. Yet the Thai government,
through NAPHA, provides this drug for patients who cannot tolerate
nevirapinef add.iJ:1..g f11rtl1er :Hrlarlcial strain all tlle Ilatio:nal flealfrl
budget.
Furthermore, ARV medicines are only part of effective rreatment for
HNI AIDS. While ARV rreatment reduces the incidence of
opportunistic infections, treating those infections directly can also
save patients' lives and reduce the number of hospitalizations.
Thailand is able to provide rreatment for cryptococcal meningitis, a
fatal opportunistic infection, because it can produce a cheap generic
version of fluconazole, a drug developed by Pfizer for which the patent
has expired. But certain other medicines vital for the treatment of
other opportunistic infections are still under patent in Thailand and,
therefore, too expensive to be used as part of the government
program. For example, Roche's ganciclovir is needed to treat
cytomegalovirus (CMV), a dangerous infection which can cause
blindness and death, but because it is patented it is too expensive
(2,854 Baht or $ 75 per 500mg vial) to be included in the government's
program.
While providing drug treatments is not a complete solution to the
problems posed by HIVI AIDS, there is little doubt that they provide
huge benefits to people living with HNI AIDS and to society more
generally. Drug therapies permit people with HNI AIDS to support
their families and communities; parents' lives can be prolonged and
livelihoods maintained. In addition, ARV treatment reduces the
discrimination and stigma associated with HNI AIDS, and creates an
incentive for HN testing, which enhances AIDS prevention and
control efforts.
However, as Thailand scales up and maintains treatment of people
with HIV/ AIDS, there is trouble on the horizon. In addition to its
current first-line treatments, Thailand will need access to 'second-line'
and 'third-line' treatments. This is inevitable as viruses typically
develop resistance to drugs after a period of time. According to the
World Health Organization's guidelines, treatment with first-line
regimens will eventually fail and will require a second-line regimen to
be used. Over time, increasing numbers of Thailand's population with
HIV/ AIDS will need access to second-line ARVs.
These second-line therapies were, however, developed more recently
and are patented in Tha:p-and, meaning that they cost too much for
government programs and are unaffordable for most patients. The
World Health Organization recommends seven drugs as second-line
treatments, including lopinavir which is patented in Thailand and is
very expensive. A bottle of lopinavir syrup costs 11,770 Baht ($ 310). A
loplnavir-ritonavir combination costs 17,762 baht ($ 467) per 180
capsules. The same drug combination is sold by an Indian generic
company for 5,930 baht ($ 156), but cannot be imported into Thailand
because of patent restrictions. Of the seven WHO-recommended
second-line ARVs, five are currently patented or could become
patented in Thailand in the near future. 16
There is no guarantee that Thailand will have the budget to fund new
medicines in the future. External shocks and many other factors can
play havoc with government finances. For example, the 1997
economic crisis had strong negative consequences on government
programs, and resulted in a significant reduction and reorientation in
the budget for HIV/ AIDS prevention and treatment. Between 1996
and 2002, Thailand's spending declined from lA19 million baht ($ 37.3
million) to 1,099 million baht ($ 28.9 million)17 for HIV/ AIDS medical
interventions, including ARV drugs and drugs for treatment of
opportunistic infections.
New stringent drug patent and marketing rules in a US FTA may
mean that second-line drugs and future innovations will be available
only to those who can afford the high prices associated with patented
products. The higher cost of second-line therapies and other patented
drugs may mean Thailand's treatment program will fail to sustain the
lives of people with HIV/ AIDS in the longer term.
4 Patent barriers to HIV/AIDS treatment
Various factors limit HIV/ AIDS treatment in Thailand, including
insufficient financing for health services. But patents are a significant
obstacle to treatment, and their impact is likely to get worse if the Thai
government signs a..Tl PTA with the US government containing 'TRIPS-
plus' intellectual property rules.
The big pharmaceutical companies argue that increased levels of
intellectual property protection are necessary in order to generate
revenues to finance research and development (R&D). Yet according
to their 2004 financial reports, the seven largest US pharmaceutical
companies spend, on average, only 14 per cent of their revenues on
R&D while 32 per cent is spent on marketing, advertising and
administration. They report more in profits - 18 per cent of revenue -
than they spend on R&D. 18 Moreover, much of the research
conducted by the pharmaceutical industry is in pursuit of higher-
priced versions of existing medicines ('me too' drugs) or monopoly
extensions for new uses of old drugs. For example, only 15 per cent of
the new drug applications approved by the US Food and Drug
Administration between 1989 and 2000 contained new molecular
entities and were considered likely to provide clinical improvement
over other products on the market. 19
In fact, much of the research conducted by the pharmaceutical
industry utilizes'initial research funded by the US government, which
invests nearly as much in R&D as the industry. 20 The government
also subsidizes industry investment in research by making R&D
expenditures tax-deductible (the corporate tax rate is about 34 per
cent). For medicines needed in both rich and poor countries, such as
antiretrovirals, companies recoup their expenses in the profitable
market in developed countries. Developing countries in Asia, Africa
and Latin America together account for only about 11 per cent of the
world pharmaceutical market. 21 There is little private research into
health problems specific to developing countries because they are not
lucrative markets. Research into HIV vaccines was ignored by
companies until public institutions increased their investment. Thus,
the social contract implicit in establishing patent rights - consumers
pay more for medicines for a limited period, but benefit from
innovation in return - does not apply in most of the developing world.
Since 1985, as a result of complaints by the Pharmaceutical Research
and Manufacturers Association of America (PhRMA) claiming that
weak patent protection was costing them millions of dollars in lost
revenue, the Office of the United States Trade Representative (USTR)
has pressured Thailand to strengthen its patent laws. As a result of
these complaints, US trade preferences under the General System of
Preferences (GSP) were denied to imports from Thailand in 1989 and
1991. Facing intense pressure, Thailand amended its existing patent
laws in 1992 to allow patents on pharmaceuticals, and extended
patent life from 15 to 20 years. The law was amended again in 1999 to
comply with obligations under the WTO TRIPS agreement.
Now, Thailand and most other WTO members must comply with the
provisions related to medicines in the TRIPS agreement; Least
Developed Countries have unti12016 to comply. Thus Thailand has
forfeited the possibility of producing or importing cheap generic
versions of patented medicines, except under a compulsory license.
As permitted by TRIPS, the Thai patent law currently allows
flexibilities that help lower the price of medicines, such as compulsory
licensing and parallel importation. Even though compulsory licenses
are rarely invoked, their use remains a.Tl importa.flt policy tool for
governments - and the threat of issuing such a license often serves as
bargaining leverage in negotiations with pharmaceutical companies to
induce them to reduce their prices. For example, in 2001, Canada
threatened to issue a compulsory license for a supply of the antibiotic
Cipro to respond to an anthrax scare. Eventually, Bayer, the maker of
Cipro, agreed to provide the drug at discounted prices. 22 And in
October 2005, US Senator Charles Schumer threatened to push for a
compulsory license on the avian influenza drug, Tamiflu, if its patent
holder, Roche, did not agree to allow generics companies to produce
the drug ill order to increase its supply. Roche entered negotiations
and reached agreement with several generics producers shortly
thereafter. 23
Despite pressure from Thai civil society, the Thai government has not
so far used these TRIPS'flexibilities'. However, it may need to do so
in the future as the cost of its treatment programs rise. According to a
recent World Bank report, 'by exercising compulsory licensing to
reduce the cost of second-line therapy by 90%, the Royal Thai
Government would reduce its future budgetary obligations by 3.2
billion discounted dollars (127 billion discounted baht) through the
year 2025 and cut by more than half the cost per life-year saved of the
National Access to Antiretroviral Program for People Living with
HIV/ AIDS, from $2,145 to $940 per life year saved.' 24
However, provisions in a US-Thailand FTA are likely to limit the
government's flexibility to issue compulsory licenses and would
create a number of other obstacles to production and marketing of
generic drugs. Furthermore, it could become more difficult to
challenge the validity of a patent. Thai civil society organizations
have recently managed to use alternative legal means to revoke
invalid HIV/ AIDS patents on the ARV didanosine (ddI) (see box).
The key to reducing drug prices is to create competition among
producers. Patents afford drug producers monopolistic control over
production and prices. The most effective way to reduce prices and
increase access is to promote generic competition. The current price
differences between generic and patented drugs in Thailand suggest
that the prices of vital patented drugs for alternative first-line and
second-line treatment, along with medicines for treatment of
opportunistic infections, could be as much as ten times higher than
prices with generic competition. As increasing numbers of people
with HIV/ AIDS are switched from first-line to patented sec-and-line
treatments, the costs will skyrocket. Average cost for first-line
treatments is 19,271 baht ($ 482) annually, while the average cost for
second-line treatments is 269,496 baht ($ 6,737).26
5 The problem with intellectual
property provisions in the FTA
" ...We will seek to include provisions that bring Thailand's intellectual
property and customs regimes up to the standards set in our other recent
FTAs ... " (United States Trade Representative, February 12, 2004)
Intellectual property rights provisions first entered the formal
negotiations between Thailand and the United States in January 2006.
There are strong reasons to be concerned about the impact a final
agreement may have on access to medicines in Thailand. First, a
pattern has been established in recent FTAs negotiated by the United
States whereby more stringent patent and drug-marketing rules are
imposed - rules that go far beyond those of the WTO TRIPS.
Secondly, secret leaked information27 indicates that the US-Thailand
FTA may go beyond other FTAs :in several areas by restricting
important existing flexibilities :in the drug patent and marketing rules.
The :intellectual property standards in recent US FTAs completed with
develop:ing countries exceed the obligations set by the WTO TRIPS
agreement. They also contradict the 2001 WTO Doha Declaration on
TRIPS and Public Health which affirmed the rights of governments 'to
use to the fult the provisions in the TRIPS Agreement which provide
flexibility' to 'protect public health and promote access to medicines
for all.' Moreover, includ:ing these intellectual property provisions in
FTAs contravenes US law: the Trade Promotion Authority Act (TPA)
passed by US Congress :in 2002 mandates the United States Trade
Representative (USTR) 'to respect the [Doha] Declaration on the
TRIPS Agreement and Public Health.'28
All US-FTAs completed s:ince US Congress passed the TPA:in 2002
:include the follow:ing 'TRI?S-pl~s' provisions:
• Longer patent terms. FTA provisions require governments to
extend patent protection beyond the maximum 20-year period
established under TRIPS to take account of delays in granting the
patent or granting marketing approval. Extend:ing this monopoly
period will further delay the introduction of affordable generic
medic:ines.
• Data exclusivity. FTAs create a new system of monopoly power,
separate from patents, by blocking the registration (i.e. marketing
approval) of generic medicines for at least 5 years, and possibly 10
years or more. TRIPS merely protects 'undisclosed data' from
clinical trials generated by brand-name companies against 'unfair
commercial use;' it mandates no monopoly period. Yet FTA
provisions prevent drug regulatory authorities from rely:ing on
that data to grant marketing approval to a generic drug that has
already been shown to be equivalent to the brand-name drug.
This will delay or prevent generic competition, even in the absence
of patent barriers. Unable to rely on the originator company's
data, generics producers would have to repeat unnecessary, time-
consum:ing and costly clinical trials in order to prove the safety
and efficacy of their drug to obtain marketing approval. Generics
companies, which operate on small margins, would be unlikely to
do so. ill addition, repeating such tests may be unethical because
they require people in the control group to take a placebo, even if
they have a life-threatening illness and even though an effective
drug is known. Furthermore, issuing a compulsory license would
be rendered an unviable policy toot as no authorized generic
product would be able to enter the market :in a timely way because
the compulsory license would not override the da~ protection. 29
• Linkage between marketing approval and patent status. New
provisions in FTAs prevent national drug regulatory authorities
from registering generic versions of drugs until after the patent
has expired. Regulatory authorities, which verify a drug's safety
and efficacy, must thus become 'patent police' as the burden of
enforcing private property rights is shifted from the patent owner
to the state's regulatory authority. These provisions also prevent
the effective use of compulsory licensing, because no generic drug
could obtain marketing approval during the patent term, and in
this way they delay the availability of affordable generic versions
of Ilevy ITledicil1.es llrLtil well after ttle expiry of a paterlt.
The USTR proposal on patents and related protections for medicines
was leaked following the initial discussion on this issue at the
negotiating session held between 9 and 13 January 2006 in Chiang
Mai, Thailand. A review of the proposed text reveals that the
provisions mentioned above are included, in some cases in a more
restrictive manner than in most previous US FTAs. Furthermore, the
proposal includes several provisions that have been excluded in most
previous US FTAs.
Oxfam is very concerned about the potential impact of such new and
stringent provisions in Thailand in light of the importance of generic
medicines to the nearly universal health care syste:rn. The effect of the
provisions on people living with HIVI AIDS is of particular concern.
The following analysis of the proposed provisions provides details of
our concerns.
• Patent term extension. The patent term would be extended, with
no upper limit such as that which exists in US law for
'unreasonable' delays in granting the patent or granting marketing
approval. Unlike earlier FTAs, for example that with Singapore or
the Central America Free Trade Agreement (CAFTA), the US-
Thailand FTA would extend the effective patent term to take
account of delays both in the US and in Thailand.
• Data exclusivity. There are several ways in which provisions
granting protection for clinical b'ial data (which parallels the
patent system) are designed to enhance the monopolies of brand-
name pharmaceutical companies. As a result, they will prevent the
marketing of generic drugs under a compulsory license and even
in the absence of a patent.
• Unlike the provisions of CAFTA, the scope of the data
protected is broadened to cover all 'information' and not
only 'undisclosed data.' Thus, even clinical trials published
in US scientific journals could not be used by the Thai
regulatory authority, as it often does now, to register a
generic drug.
• Data must be protected for all pharmaceutical products
that are introduced in Thailand, not only for new
L."'lllovative drugs. Data protection applies even if the
product is on the market in the US or other countries, and
even if the product is simply a combination of chemical
entities already available in Thailand.
• The proposed period of protection is 'at least five years'
starting from the date of marketing approval in each
country. This goes beyond the maximum of five years
required under US law. For Thailand, this coutd amount to
almost 10 years of protection if the pharlllaceutical
company seeking marketing approval waits until its five
years of protection in the US is about to expire before
registering its drug in Thailand.
• Three additional years of monopoly protection are granted
to the company of origin if it finds a new clinical use for a
drug already on the market in some form and if new
clinical trials are needed to gain marketing approval for the
new use (for example, use by. children). This requirement
goes beyond the US FTAs wiL.~Singapore, L.1.e AndefuL
countries and Central America.
• Linkage. Thailand's drug regulatory authority would become the
'patent police' to protect patent holders. It would be required to
investigate and confirm that there are no existing patent claims
implicated in a new generic product. If any claims exist, valid or
not, Thailand would have to deny marketing approval. The
regulatory authority would also have to notify the patent holder
directly of the identity of the potential infringing registration.
• Restrictions on the grounds for compulsory licensing. These
provisions would strictly limit Thailand's use of this important
TRIPS safeguard that allows a government to override a patent,
without any restrictions of the grounds upon which it can grant
such a license, as long as the patent holder is given'adequate'
compensation. Unlike CAFTA or other US FTAs, these provisions
would limit the use of a compulsory license only to remedy anti-
competitive practices, for public non-commercial use, for a
'national emergency' or in a case of'extreme urgency.' For the
latter purposes, there would be limits on private sector use of the
license and the patent holder would not be required to disclose
information or technical know-how regarding the patent, all of
which may delay or render its use ineffective. Such restrictions
could undermine the government's ability to bargain for cheaper
patented drugs or to promote competition by generic producers
which could reduce prices and increase access to medicines.
• Expansion of patent scope. Unlike PTAs with Singapore or
CentralAmerica, a new provision would require granting patents
for new uses or new methods of using an existing known product.
30 This would allow pharmaceutical companies to engage in
deliberate strategies to prolong indefinitely or ' evergreen' their
monopolies by granting additional 20-year patents for new
therapeutic uses of old drugs, without any requirement for
innovation.
• Limits to challenging potentially invalid patents. Unlike
CAPTA, no challenges to patent validity would be permitted prior
to granting the patent. Thai law currently allows for such legal
procedures, which helps to avoid invalid granting of patents and
delays to generic competition. 31
6 Rights and wrongs
Patents are a legal creation. The patent system creates a 'property
right' over knowledge in order to encourage people to invent and
produce. Creators of knowledge have a legitimate interest in
benefiting from their investment and labors. Because intellectual
property is not physically tangible and can be used by many people
simultaneously at no additional cost, a temporary monopoly license is
required to prevent others from using it. But the system to protect
intellectual property rights exists for the sake of society, not for the
enrichment of a few.
Patent and other intellectual property rights mechanisms offer legal
monopolies in order to provide innovators with a return on their
knowledge investment The intention is to serve as an incentive for
future innovation. The counter-balancing interest of society is in the
proliferation of useful innovations. From an economic perspective,
there is an inherent tension between monopoly rights and competition
that leads to efficiency in the market. There is a trade-off between
incentives for innovation, which the monopoly license is meant to
provide, and competitive access to new technologies that benefit
society. When it comes to medicines, however, the trade-off is in
public health.
Thus, intellectual property rights with regard to medicines can come
into'conflict with other rights, notably the right to health. The right to
health has been recognized as a fundamental human right, and is
enshrined in a number of treaties, including the Constitution of the
World Health Organization, the United Nations Charter,32 the
Universal Declaration on Human Rights, 33 and the Convention on the
Rights of the Child. 34 The most important human rights instrument
that explicitly recognizes the right to health is the International
Covenant on EconoInic, Social and Cultural Rights (ICESCR). Article
12 of the ICESCR creates a legally binding right to health, and Article
2 imposes legal obligations on all States parties to co-operate
internationally to realize this right.
The right to health was defined as 'a right to the enjoyment of a
variety of facilities, goods, services and conditions necessary for the
realization of the highest attainable standard of health.' This includes
'a system of urgent medical care in cases of accidents, epidemics and
similar health hazards,' as well as 'the provision of essential drugs' for
prevalent diseases. 35 In Apri12001, the 57th Session of the United
Nations Commission on Human Rights adopted Resolution2001j33,
on'Access to Medication in the Context of Pandemics such as
HIV j AIDS', which confirmed that'access to medication in the context
of HNj AIDS is one fundamental element for achieving progressively
the full realization of the right of everyone to the enjoyment of the
highest attainable standard of physical and mental health.' 36
Thailand ratified the ICESCR on 5 September 1999, and under Article
12 it has an obligation to make sure that its people have access to
pharmaceuticals and healthcare services. The right to health under
internati~nallawis guaranteed by the Thai constitution. The 1997
Constitution, known as the People's Constitution, recognizes the right
to health in Article 52. The constitutional right to health was outlined
and implemented in the eighth National Economic and Social
Development Plan and the National Plan for AIDS Prevention and
Alleviation. The link between the national AIDS plan and the national
development plan reflected the view of the Thai government that the
HN/ AIDS epidemic was not only a medical crisis, but also a threat to
the sustainable} social and economic development of the country.
At the request of Thai NGOs and NGOs from other countries
negotiating FTAs with Thailand, the UN Special Rapporteur on the
Right to Health sent a communication to the Thai government in
October 2005 raising concern that other bilateral PTAs had omitted
important public health safeguards and that this could threaten the
enjoyment of the right to health. He recommended that all fullire
trade agreements should safeguard respect for the right to health and
access to essential medicines in particular.37
In addition, the UN Committee on the Rights of the Child, which
monitors the implementation of the Convention on the Rights of the
Child, recommended in January 2006 that the Thai government
should'ensure that regional and other free trade agreements do not
have a negative impact on the enjoyment of the right to health of
children. More specifically, the Committee recommended that the
Thai government ensure that such agreements will not negatively
impact the availability of drugs and medicines for children.'38
Therefore, in negotiating an PTA with the United States, Thailand
should ensure that it can maintain and enact laws and policies that
uphold the right to public health and promote broad access to safe,
effective, and affordable medicines. Thailand's current patent
legislation incorporates safeguard mechanisms to that end. Including
provisions such as those contained in the US proposal which would
require more strict intellecllial property protection in Thai legislation
would be the wrong policy choice for the many thousands of Thais
living with HN/ AIDS, as well as for those suffering from other
infectious and chronic diseases.
7 Conclusion
Oxfam shares the concerns of Thai NGOs that a Free Trade
Agreement with the United States containing new stringent
intellecllial property rules could seriously undermine future access to
affordable medicines in Thailand. Oxfam urges the United States to
stop pressuring Thailand to implement 'TRIPS-plus' measures in the
FTA, and instead to give maximum support to Thailand to use-the
flexibilities contained in TRIPS, such as compulsory licensing, in order
to expand and ensure the sustainability of the Thai AIDS program that
has successfully used generic medicines.
The case of HNj AIDS in Thailand illustrates how stringent
intellectual property protection could block access to affordable! life-
saving medicines. But the problem is not limited to this disease. Thai
people need other medicines to treat heart disease! diabetes! and
cancer! for example. The rising incidence of resistant infections and
chronic disease also require new! effective! and affordable medicines.
Many of these medicines are! and will be! under patent and therefore
too expensive for those who need them.
Oxfam therefore supports the call from Thai civil society
organizations for the Thai government to make maximum use of
compulsory licensing and other public health safeguards in order to
allow poor people to gain access to affordable generic medicines!
and to reject new 'TRIPS-plus! measures in the US-Thailand FTA.
Thailand already complies with the WTO TRIPS Agreement so there
is no need for additional intellectual property provisions in an FTA -
except to provide short-term commercial benefit to big pharmaceutical
companies - to the detriment of Thai people. No FTA should trade
away public health.
8 Recommendations
Thailand and the United States should halt FTA negotiations i.."'1. order
to carry out and take into account independent studies on the
potential impact of proposed FTA provisions on public health.
Greater transparency is necessa..-ry throughout all PTA negotiations by
disclosing the negotiating text to the public and making it available to
all stakeholders. Furthermore! the concerns and proposals of civil
society stakeholders should be taken into account in all negotiations.
It is already clear from the leaked US negotiating proposal that the
FTA could have serious implications for public health in Thailand!
particularly in the treatment of HNj AIDS. Before considering the
adoption of such new policies, a much broctder public debate is
needed.
Any trade agreement negotiated between the United States and
Thailand should not include any 'TRIPS-plus' measures, but rather
should expressly include in the text affirmative support for Thailand's
right to use the flexibilities provided under the WTO TRIPS
Agreement, the Doha Declaration and its subsequent 30th August
Decision! known as the !TRIPSjhealth solution'. Furthermore,
Thailand should consider exercising its right to the full use of
compulsory licensing and should retain the discretion to determine
the grounds upon which it can be used. No trade agreement should in
any way serve to limit generic competition.
Obligations contained in other chapters of a potential trade
agreement, particularly the investment and dispute settlement
chapters, must not undermine the right of governments to use public
health safeguards available to them under global trade rules.
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